World Investment Advisors LLC Buys New Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

World Investment Advisors LLC bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 33,249 shares of the company’s stock, valued at approximately $1,614,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after buying an additional 273 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its holdings in Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares during the last quarter. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $55,000. Blue Trust Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. bought a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth about $78,000. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $42.24 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a 50 day simple moving average of $47.14 and a two-hundred day simple moving average of $44.63. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 14.08, a P/E/G ratio of 0.87 and a beta of 0.78.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AMPH. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $60.33.

Insider Activity at Amphastar Pharmaceuticals

In other news, EVP Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total value of $336,929.84. Following the completion of the transaction, the executive vice president now owns 118,388 shares of the company’s stock, valued at $5,786,805.44. The trade was a 5.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now directly owns 74,938 shares in the company, valued at $3,900,522.90. This trade represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,533 shares of company stock valued at $1,676,542 in the last 90 days. Corporate insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.